Fig. 9From: Matrine combined with cisplatin synergistically inhibited urothelial bladder cancer cells via down-regulating VEGF/PI3K/Akt signaling pathwayThe interactions between the drugs and PI3K(4J6I) in the binding site. Ten random poses of matrine docked into the active site of 4J6I (a). The binding modes of matrine in PI3K: at least one residue involved in the interactions in ten random poses, Lys890 (h-bonds) (b). Ten random poses of cisplatin docked into the same active site of 4J6I (c). The binding modes of cisplatin in PI3K: at least eight residues involved in the interactions in ten random poses, Lys802, Lys833, Asp836, Asp884 Ala885, Lys890 and Asp964 (h-bonds), and Tyr867 (π–π interaction) (d)Back to article page